Tvito Ariella, Rowe Jacob M
a Department of Hematology , Shaare Zedek Medical Center , Jerusalem , Israel.
b Department of Hematology and Bone Marrow Transplantation , Rambam Health Care Campus , Haifa , Israel.
Expert Opin Biol Ther. 2017 Dec;17(12):1557-1564. doi: 10.1080/14712598.2017.1387244. Epub 2017 Nov 1.
Acute lymphoblastic leukemia (ALL) is an uncommon disorder that affects about 20% of adults with acute leukemia. Historically, those who relapse from this condition have a dismal prognosis. Recent developments in immunoconjugate usage has changed the landscape of lymphoid B-cell malignancy therapy. One recent development is the FDA approved therapy inotuzumab ozogamicin which has the potential to reduce the overall toxicity of intensive regimens for ALL, as well as to possibly increase the number of patients who may achieve a state of minimal residual disease. Areas covered: In this review, the pre-clinical and clinical experiences with inotuzumab ozogamicin in lymphoma and ALL are reviewed. The article further includes the published phase I, II and III studies in ALL and considers the safety and efficacy of this treatment. Expert opinion: Inotuzumab ozogamicin is likely to be used, primarily, as a potent agent for relapsed ALL, either as the first choice or for those who fail treatment with blinatumumab. Its potential in newly diagnosed patients is currently unknown, such that the overall impact is likely to be important, but limited.
急性淋巴细胞白血病（ALL）是一种罕见的疾病，约占成年急性白血病患者的20%。从历史上看，那些病情复发的患者预后很差。免疫偶联物应用方面的最新进展改变了淋巴B细胞恶性肿瘤的治疗格局。最近的一项进展是美国食品药品监督管理局（FDA）批准的治疗药物奥英妥珠单抗，它有可能降低ALL强化治疗方案的总体毒性，并可能增加达到微小残留病状态的患者数量。涵盖领域：在本综述中，对奥英妥珠单抗在淋巴瘤和ALL中的临床前和临床经验进行了综述。本文还包括已发表的ALL的I期、II期和III期研究，并探讨了该治疗方法的安全性和有效性。专家观点：奥英妥珠单抗可能主要用作复发ALL的有效药物，既可以作为首选，也可用于对blinatumumab治疗无效的患者。其在新诊断患者中的潜力目前尚不清楚，因此总体影响可能很重要，但也有限。
